

=> d his

(FILE 'HOME' ENTERED AT 11:40:20 ON 03 MAY 2004)

FILE 'REGISTRY' ENTERED AT 11:40:28 ON 03 MAY 2004

L1 STRUCTURE UPLOADED

L2 0 S L1


L3 50 S L1 FULL

FILE 'CAPLUS' ENTERED AT 11:41:20 ON 03 MAY 2004

L4 1 S L3

=> d que 14 stat

L1 STR



Structure attributes must be viewed using STN Express query preparation.

L3 50 SEA FILE=REGISTRY SSS FUL L1

L4 1 SEA FILE=CAPLUS ABB=ON PLU=ON L3

=> d bib abs hitstr

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2003:202470 CAPLUS

DN 138:238169

TI Method for producing diaryl cycloalkyl derivatives of oxazole and the use thereof as PPAR activators

IN Glombik, Helner, Falk, Eugen; Frick, Wendelin; Keil, Stefanie; Schaefer, Hans-Ludwig; Schwink, Lothar; Wendler, Wolfgang

PA Aventis Pharma Deutschland GmbH, Germany

S0 PCT Int. Appl., 83 pp.

CODEN: PIXXD2


DT Patent

LA German

FAN CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WD	2003020269	AI	20030313
			WD	2002-EP9221 20020817
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GO, GW, ML, MR, NE, SN, TD, TG		
	DE	10142734	AI	20030327
	DE	10223273	AI	20031204
	US	2003144332	AI	20030731
	US	6624185	B2	20030923
PRAI	DE	2001-10142734	A	20010831
	DE	2002-10223273	A	20020524
OS	MARPAT	138:238169		
GI				

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



AB The invention relates to diaryl cycloalkyl derivs. and their physiol. compatible salts and physiol. functional derivs. The invention also relates to oxazoles I [Z = C3-8-alkyl, C3-8-alkenyl (rings may contain 1 or more oxygens); R1, R2, R4, R5 = H, F, Cl, Br, OH, NO2, CF3, OCF3, C1-6-alkyl, O-(C1-6-alkyl); R3 = H, C1-6-alkyl (chains may contain 1 or more oxygens)] to their physiol. compatible salts and to a method for producing the same. Thus, (+)-cis-oxazole II was prepared from cyclohexane-1,3-diol via O-alkylation with 4-(iodomethyl)-2-(4-fluorophenyl)oxazole, separation of cis/trans isomers, HPLC resolution of the cis isomers, and finally alkylation of the (-)-cis isomer with Me 2-(bromomethyl)-6-methylbenzoate. The compds. have lipid and/or triglyceride reducing properties and are suitable e.g. for treating lipid metabolic disorders, type II diabetes and syndrome X. The bioactivity of II was determined [EC50 = 0.3 nM vs. PPAR α].


IT 501362-02-3P 501362-03-4P 501362-06-7P
501362-09-0P 501362-12-5P 501362-15-8P
501362-16-9P 501362-21-6P 501362-27-2P
501362-28-3P 501362-30-7P 501362-31-8P
501362-36-3P 501362-37-4P 501362-38-5P
501362-39-6P 501362-43-2P 501362-45-4P
501362-46-5P 501362-47-6P 501362-48-7P
501362-49-8P 501362-50-1P 501362-52-3P
501362-53-4P 501362-54-5P 501362-55-6P
501362-58-9P 501362-59-0P 501362-60-3P
501362-61-4P 501362-62-5P 501362-65-8P
501362-67-0P 501362-70-5P 501362-73-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
(Therapeutic use): BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. and PPAR activating activity of; prepn. of oxazole diaryl cycloalkyl derivs. and the use thereof as PPAR activators)

RN 501362-02-3 CAPLUS


CN Benzoic acid, 2-[[[3-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)



RN 501362-03-4 CAPLUS

CN Benzoic acid, 2-[[[3-[[2-(4-methoxyphenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 501362-06-7 CAPLUS

CN Benzoic acid, 2-methyl-6-[[[3-[[2-phenyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501362-09-0 CAPLUS

CN Benzoic acid, 2-methyl-6-[[[3-[[2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 501362-12-5 CAPLUS

CN Benzoic acid, 2-[[[3-[[2-(4-fluorophenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 501362-15-8 CAPLUS

CN Benzoic acid, 5-[[[3-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-2-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 501362-16-9 CAPLUS

CN Benzoic acid, 2-[[[3-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-5-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 501362-21-6 CAPLUS

CN Benzoic acid, 2-[[[[(1R,3R)-3-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl-, rel- (9C1) (CA INDEX NAME)


Relative stereochemistry.



RN 501362-27-2 CAPLUS

CN Benzoic acid, 2-methyl-6-[[[[(1R,2R)-2-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-, rel- (9C1) (CA INDEX NAME)


Relative stereochemistry.



RN 501362-28-3 CAPLUS

CN Benzoic acid, 2-[[[4-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl-, rel- (9C1) (CA INDEX NAME)


L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 501362-37-4 CAPLUS

CN Benzoic acid, 2-[[[trans-4-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclohexyl]methoxy]-6-methyl-, rel- (9C1) (CA INDEX NAME)


Relative stereochemistry.



RN 501362-38-5 CAPLUS

CN Benzoic acid, 2-[[[2-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclohexyl]ethoxy]-6-methyl-, rel- (9C1) (CA INDEX NAME)


Relative stereochemistry.




RN 501362-39-6 CAPLUS

CN Benzoic acid, 2-[[[2-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclohexyl]ethoxy]-6-methyl-, rel- (9C1) (CA INDEX NAME)

Relative stereochemistry.




L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 501362-30-7 CAPLUS


CN Benzoic acid, 2-[[[5-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclooctyl]oxy]methyl]-6-methyl-, rel- (9C1) (CA INDEX NAME)



RN 501362-31-8 CAPLUS

CN Benzoic acid, 2-[[[5-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclooctyl]oxy]methyl]-6-methyl-, rel- (9C1) (CA INDEX NAME)

Relative stereochemistry.



RN 501362-36-3 CAPLUS


CN Benzoic acid, 2-[[[5-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclohexyl]methoxy]-6-methyl-, rel- (9C1) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


RN 501362-43-2 CAPLUS

CN Benzoic acid, 2-[[[3-[[2-(4-bromophenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl-, rel- (9C1) (CA INDEX NAME)




RN 501362-45-4 CAPLUS

CN Benzoic acid, 2-[[[3-[[2-(3-fluorophenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl-, rel- (9C1) (CA INDEX NAME)




RN 501362-46-5 CAPLUS

CN Benzoic acid, 2-[[[3-[[2-(3-methoxyphenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl-, rel- (9C1) (CA INDEX NAME)



RN 501362-47-6 CAPLUS


CN Benzoic acid, 2-methyl-6-[[[3-[[5-methyl-2-[3-(trifluoromethyl)phenyl]-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-, rel- (9C1) (CA INDEX NAME)




RN 501362-48-7 CAPLUS

CN Benzoic acid, 2-[[[3-[[2-(3-chlorophenyl)-5-methyl-4-


L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)




RN 501362-49-8 CAPLUS
 CN Benzoic acid, 2-[[[3-[[2-(4-chlorophenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)




RN 501362-50-1 CAPLUS
 CN Benzoic acid, 2-methyl-6-[[[3-[[5-methyl-2-(3-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]- (9CI) (CA INDEX NAME)




RN 501362-52-3 CAPLUS
 CN Benzoic acid, 2-[[[3-[[2-(3,4-dimethylphenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)




L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 501362-59-0 CAPLUS
 CN Benzoic acid, 2-[[[3-[[2-(3-cyanophenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)



RN 501362-60-3 CAPLUS
 CN Benzoic acid, 2-methyl-6-[[[3-[[5-methyl-2-phenyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]- (9CI) (CA INDEX NAME)




RN 501362-61-4 CAPLUS
 CN Benzoic acid, 2-methyl-6-[[[3-[[2-(4-methoxyphenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]- (9CI) (CA INDEX NAME)




RN 501362-62-5 CAPLUS
 CN Benzoic acid, 2-[[[3-[[2-(4-methoxyphenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 RN 501362-53-4 CAPLUS
 CN Benzoic acid, 2-[[[3-[[2-(2,4-dimethylphenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)



RN 501362-54-5 CAPLUS
 CN Benzoic acid, 2-methyl-6-[[[3-[[5-methyl-2-(2-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]- (9CI) (CA INDEX NAME)




RN 501362-55-6 CAPLUS
 CN Benzoic acid, 2-methyl-6-[[[3-[[5-methyl-2-(3-(trifluoromethoxy)phenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]- (9CI) (CA INDEX NAME)




RN 501362-58-9 CAPLUS
 CN Benzoic acid, 2-[[[3-[[2-(3,4-dimethoxyphenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 501362-65-8 CAPLUS
 CN Benzoic acid, 2-[[[3-[[2-(4-methoxyphenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501362-67-0 CAPLUS
 CN Benzoic acid, 2-methyl-6-[[[3-[[2-(4-methoxyphenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501362-70-5 CAPLUS
 CN Benzoic acid, 2-methyl-6-[[[3-[[2-(4-methoxyphenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 501362-73-8 CAPLUS

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 CN Benzoic acid, 2-[[[(1S,3R)-3-[[2-(4-fluorophenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl-, (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 501362-01-2P 501362-08-9P 501362-11-4P
 501362-14-7P 501362-19-2P 501362-20-5P
 501362-42-1P 501362-69-2P 501362-72-7P
 501362-75-0P 501362-77-2P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and saponification of; preparation of oxazole diaryl cycloalkyl derivs. and the use thereof as PPAR activators)
 RN 501362-01-2 CAPLUS
 CN Benzoic acid, 2-[[[(1S,3R)-3-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 501362-08-9 CAPLUS
 CN Benzoic acid, 2-methyl-6-[[[(1S,3R)-3-[[2-(phenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 501362-20-5 CAPLUS
 CN Benzoic acid, 2-[[[(1R,3S)-3-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-5-methyl-, ethyl ester, rel. (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 501362-42-1 CAPLUS
 CN Benzoic acid, 2-[[[(1R,3S)-3-[[2-(4-bromophenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 501362-69-2 CAPLUS
 CN Benzoic acid, 2-methyl-6-[[[(1R,3S)-3-[[2-(phenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 501362-11-4 CAPLUS
 CN Benzoic acid, 2-methyl-6-[[[(1S,3R)-3-[[2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501362-14-7 CAPLUS
 CN Benzoic acid, 2-[[[(1R,3S)-3-[[2-(4-fluorophenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 501362-19-2 CAPLUS
 CN Benzoic acid, 5-[[[(1R,3S)-3-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-2-methyl-, ethyl ester, rel. (9CI) (CA INDEX NAME)


Relative stereochemistry.

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 501362-72-7 CAPLUS
 CN Benzoic acid, 2-methyl-6-[[[(1R,3S)-3-[[2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501362-75-0 CAPLUS
 CN Benzoic acid, 2-[[[(1S,3R)-3-[[2-(4-fluorophenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 501362-77-2 CAPLUS
 CN Benzoic acid, 2-[[[(1R,3S)-3-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




IT 501362-44-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation, cyanolysis and PPAR activating activity of; preparation of oxazole diaryl cycloalkyl derivs. and the use thereof as PPAR activators)

RN 501362-44-3 CAPLUS

CN Benzoic acid, 2-[[[3-[[2-(3-bromophenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)



IT 501362-64-7P 501362-78-3P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation, methanolysis and PPAR activating activity of; preparation of oxazole diaryl cycloalkyl derivs. and the use thereof as PPAR activators)

RN 501362-64-7 CAPLUS

CN Benzoic acid, 2-[[[3-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 501362-78-3 CAPLUS

CN Benzoic acid, 2-[[[3-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> => d his

(FILE 'HOME' ENTERED AT 11:40:20 ON 03 MAY 2004)

FILE 'REGISTRY' ENTERED AT 11:40:28 ON 03 MAY 2004

L1 STRUCTURE UPLOADED
L2 0 S L1
L3 50 S L1 FULL

FILE 'CAPLUS' ENTERED AT 11:41:20 ON 03 MAY 2004

L4 1 S L3
E GLOMBIK HEINER/AU
L5 51 S E3
E FALK EUGEN/AU
L6 31 S E3-E4
E FRICK WENDELIN/AU
L7 40 S E3
E KEIL STEFANIE/AU
L8 3 S E3
E SCHAFER HANS LUDWIG/AU
L9 4 S E3
E SCHWINK LOTHAR/AU
L10 16 S E3
E WENDLER WOLFGANG/AU
L11 9 S E3-E4
L12 123 S L5 OR L6 OR L7 OR L8 OR L9 OR L10 OR L11
L13 3 S L12 AND DIARYL?

=> d 1-3 bib abs

L13 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2004:101141 CAPLUS

DN 140:163866

TI Preparation of 1,3-dihydro-1,3-diphenyl-2H-imidazol-2-ones and related

compounds as MCH receptor modulators for the treatment of obesity

IN Schwink, Lothar; Stengelin, Siegfried; Gossel, Matthias; Boehme,

Thomas; Hessler, Gerhard; Rosse, Gerard; Walser, Armin

PA Aventis Pharma Deutschland G.m.b.H., Germany

SO PCT Int. Appl., 113 pp.

CODEN: PIXXD2

DT Patent

LA German

FAN: CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004011438	A1	20040205	WO 2003-EP7891	20030718
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ				
RW: GH, GM, KE, LS, MA, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG				
DE 10233817	A1	20040212	DE 2002-10233817	20020725
WO 2004012648	A2	20040212	WO 2003-EP7639	20030715
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ				
RW: GH, GM, KE, LS, MA, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG				


PRAI DE 2002-10233817 A 20020725

OS MARPAT 140:163866

GI

L13 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN

(Continued)



AB Title compds. I [R = alkyl, alkylaryl, cycloalkyl, etc.; A = (C(R2)(R43))_m; m = 0-5; R42, R43 = H, alkyl, aryl; B = a bond or a link, i.e. S, SO, SO₂, etc.; W = (CH₂)_n, CH=CH, CH=N, etc.; n = 2-5; R9, R10 = H, alkyl, alkoxyalkyl, etc.; R1, R2, R3, R4 = H, halo, OH, etc.; R5, R6, R7, R8 = H, halo, OH, etc.] and their pharmaceutically acceptable salts and formulations were prepared. For example, TFA catalyzed cyclization of di-Me acetal II, e.g., prepared from 4-phenoxyaniline in 2-steps, afforded diarylcyclic urea III. In milk consumption studies with female NMRI mice, cyclic urea III exhibited very good anorectic effects, i.e., 58% decrease in milk consumption vs control. Compds. I are claimed useful as antiobesity and antidiabetic agents.

RE: CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2003:202470 CAPLUS

DN 138:238169

TI Method for producing diaryl cycloalkyl derivatives of oxazole

and the use thereof as PPAR activators

IN Glombik, Heiner; Falk, Eugen; Frick, Wendelin

; Keil, Stefanie; Schaefer, Hans-Ludwig; Schwink,

Lothar; Wendler, Wolfgang

PA Aventis Pharma Deutschland GmbH, Germany

SO PCT Int. Appl., 83 pp.

CODEN: PIXXD2

DT Patent

LA German

FAN: CNT 1


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003020269	A1	20030313	WO 2002-EP9221	20020817
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MA, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG				
DE 10142734	A1	20030327	DE 2001-10142734	20010831
DE 10223273	A1	20031204	DE 2002-10223273	20020524
US 2003144332	A1	20030731	US 2002-231432	20020830
US 6624185	B2	20030923		
PRAI DE 2001-10142734	A	20010831		
DE 2002-10223273	A	20020524		

OS MARPAT 138:238169

GI

L13 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN

(Continued)




AB The invention relates to diaryl cycloalkyl derivs. and their physiol. compatible salts and physiol. functional derivs. The invention also relates to oxazoles I [Z = C3-8-alkyl, C3-8-alkenyl (rings may contain 1 or more oxygens); R1, R2, R4, R5 = H, F, Cl, Br, OH, NO₂, CF₃, OCF₃, C1-6-alkyl, O-(C1-6-alkyl); R3 = H, C1-6-alkyl; X, Y = C1-6-alkyl (chains may contain 1 or more oxygens)] to their physiol. compatible salts and to a method for producing the same. Thus, (+)-cis-oxazole II was prepared from cyclohexane-1,3-diol via O-alkylation with 4-(iodomethyl)-2-(4-fluorophenyl)oxazole, separation of cis/trans isomers, HPLC resolution of the cis isomers, and finally alkylation of the (-)-cis isomer with Me 2-(bromomethyl)-6-methylbenzoate. The compds. have lipid and/or triglyceride reducing properties and are suitable e.g. for treating lipid metabolic disorders, type II diabetes and syndrome X. The bioactivity of II was determined (EC₅₀ = 0.3 nM vs. PPARα).

RE: CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2000-241189 CAPLUS
 DN 132:279546
 TI Preparation of 1,3-diaryl-2-pyridin-2-yl-3-(pyridin-2-ylamino)propanols and amino acid and peptide derivatives thereof as antihyperlipidemics.
 IN Kirsch, Reinhard; Enhsen, Alfons; Głombik, Heiner; Kramer, Werner; Falk, Eugen
 PA Aventis Pharma Deutschland GmbH, Germany
 SO PCT Int. Appl., 84 pp.
 CODEN: PIXXD2
 DT Patent
 LA German
 FAN, CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000020393	A1	20000413	WO 1999-EP6933	19990918
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
DE 19845406	A1	20000413	DE 1998-19845406	19981002
DE 19845406	C2	20011018		
CA 2345985	AA	20000413	CA 1999-2345985	19990918
AU 9961926	A1	20000426	AU 1999-61926	19990918
AU 757689	B2	20030306		
BR 9915027	A	20010717	BR 1999-15027	19990918
EP 1117642	A1	20010725	EP 1999-948791	19990918
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002526530	T2	20020820	JP 2000-574510	19990918
RU 2224748	C2	20040227	RU 2001-111841	19990918
US 6596728	B1	20030722	US 1999-410083	19991001
ZA 2001002587	A	20011105	ZA 2001-2587	20010329
PRA1 DE 1998-19845406	A	19981002		
WO 1999-EP6933	W	19990918		
OS MARPAT 132:279546				
GI				

L13 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



AB Title compds. [1: R = Eq(A4)p(A3)o(A2)n(A1)mZ1; Z = NHACO, COACO, COOCO; A = alkylene; O = phenylene; A1-A4 = (protected) amino acid residue; E = SO2R4, COR4; R1 = (substituted) Ph, thiazolyl, oxazolyl, thienyl, furyl, pyridyl, pyrimidinyl; R2 = H, OH, CH2OH, OMe; R3 = H, F, Me, OMe; R4 = alkyl, AR5, COAR5, etc.; R5 = CO2R6, COR6, (substituted) alkyl, Ph, naphthyl, thienyl, furyl, pyridyl, pyrimidinyl, chromanyl, thiazolyl, etc.; R6 = H, alkyl; l, m, n, o, p = 0, 1; l+m+n+o+p ≤ 1], were prepared. Thus, 1 (R = H; R1 = Ph; R2, R3 = H) (preparation given) was treated with FMOC-D-Lys(BOC)-OH, TOTU, and Et3N in DMF followed by deprotection with piperidine in DMF to give 63.5% 1 [R = H-D-Lys(BOC); R1 = Ph; R2, R3 = H]. The latter was treated as above to give 43% 1 [R = H-D-Lys(BOC)-D-Lys(BOC); R1 = Ph; R2, R3 = H]. 1 inhibited [3H]-taurocholate uptake in rabbit ileum preps, with quotients of IC50Na values of taurochenodesoxycholate and 1 of 0.16-1.26.

RE CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT